Drug Profile
KVD 818
Alternative Names: KVD818Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator KalVista Pharmaceuticals
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hereditary angioedema
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Hereditary-angioedema(Prevention, In volunteers) in United Kingdom (PO)
- 11 Aug 2016 Phase-I clinical trials in Hereditary angioedema (Prevention, In volunteers) in United Kingdom (PO)
- 11 Aug 2016 Kalvista Pharmaceuticals plans a phase II trial in Hereditary angioedema